Using the Patients Own Lymphocytes as Immunotherapy in Advanced GI Cancers
Patients with metastatic cancer commonly have had multiple treatment regimes. Unfortunately, situations arise where ultimately treatment options are exhausted and unsuccessful, leaving a person fearful and anxious about their long-term survival.
So while standard treatments may be exhausted, today, clinical testing of new cancer therapy innovations are achieving greater and greater successes with difficult to treat cancers. Multiple medical institutions and universities are treating patients with these new medical interventions analyzing and testing their potential efficacy in disease treatment. Participation is voluntary, and without continued obligation.
Table of Contents:
Clinical Testing
Clinical trials testing a drug for the first time follow strict guidelines
Phase 1 involves testing healthy volunteers to determine if it works in the body and its safety.
Phase 2 involves treating people with the disease and assessing its effectiveness and safety.
Phase 3 confirms its performance in the disease, continues monitoring safety and sees how it compares with current standard treatments.
Phase 4 occurs as the result of FDA approval, and while the treatment is considered safe for most people, continued monitoring is maintained for any side effects that might occur over time.
Date: 04/01/2025
Source: Nature Medicine. April 1, 2025. DOI: 10.1038/s41591-025-03627-5.
Summary
Even with advances in cancer therapies, situations arise where a patient's cancer spreads, despite treatment with multiple available options. At this juncture, your oncologist could consider recommending an ongoing clinical trial associated with your type of cancer.
This article references a clinical trial which is using a personalized immunotherapy combined with an immune checkpoint inhibitor, Keytruda. Researchers identified and selected specific immune cells, tumor infiltrating lymphocytes(TIL’s) which could recognize and target an individual’s cancer cell’s surface receptors and attack the tumor. Scientists then grew that individual’s specific TIL's in large quantities in the laboratory, and re-infused them back into that patient.
The clinical trial included a total of 91 patients, with several metastatic GI tumors, colon, rectum, stomach,esophageal and pancreas who had had four prior unsuccessful chemotherapies.
In the pilot study, 18 patients were treated with TILs without specific anti tumor activity and there was no objective reduction in tumor size.
In the second phase, patients treated with selected TIL therapy. 7.7% had an objective response.
In the trial's second phase, patients received pembrolizumab, Keytruda, followed by the infusion of TILs. Keytruda is a checkpoint inhibitor drug that helps unblock immune system inhibition and allow an augmentation of its ability to attack cancer cells, and results showed that 24% of patients had an objective response.
And in the second and third phase of testing, patients specifically having colon, rectal, pancreas and biliary cancers had responses that lasted 8 months to more than 5.8 years, when treated with TILs alone ,while the TIL /Keytruda combination had responses lasting 4 months to 3.5 years.
However, 30% of patients treated with selective TILs had serious side effects.
Amtagvi, Lifileucel is the first cellular therapy for a solid tumor made from a patient’s TILs was approved last year by the FDA for advanced melanoma. The clinical trial involved 70 patients and 30% had some reduction in tumor size, with a complete response in 10%. And at one year, 40% of those that responded had no progression of their disease, with only one treatment infusion.